Literature DB >> 35372925

Venous Thrombotic Events in ANCA-Associated Vasculitis: Incidence and Risk Factors.

Bradley Isaacs1, Eric J Gapud1, Brendan Antiochos1, Philip Seo1, Duvuru Geetha2.   

Abstract

Background: The incidence of venous thromboembolism (VTE) is increased in ANCA-associated vasculitis (AAV). We assessed the frequency of VTE observed among patients with AAV evaluated at our center and identified risk factors.
Methods: Patients from the Johns Hopkins Vasculitis Center cohort who were evaluated between 1998 and 2018 and had a diagnosis of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) were eligible for analysis. Baseline demographics and clinical and serologic data were extracted. Univariate and multivariate analyses were performed to identify factors associated with VTE in AAV.
Results: A total of 162 patients with AAV were identified, 105 (65%) with GPA; 22 (14%) of these patients had a recorded VTE with a median time to VTE of 1 month. The mean (SD) age in the VTE versus non-VTE groups was 54±20 versus 55±17 years (P=0.99), 64% versus 60% female (P=0.93), 82% versus 49% PR3-ANCA positive (P=0.01), with a total mean BMI of 33.3±5.7 versus 28.3±6.1 kg/m2, (P<0.001) respectively. The median Birmingham Vasculitis Activity Score (BVAS version 3) was 19 versus 14 (P=0.02). Univariate analyses identified PR3-ANCA, rapidly progressive GN (RPGN), and hypoalbuminemia. In multivariate analysis, the significant associations with VTE included PR3-ANCA (OR, 4.77; P=0.02), hypoalbuminemia (OR, 4.84; P=0.004), and BMI (OR, 1.18; P<0.001). Conclusions: VTE is a surprisingly common complication of AAV. PR3-ANCA and hypoalbuminemia are risk factors for developing VTEs. Further studies are needed to confirm these findings. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/K360/2020_04_30_KID0000572019.mp3.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  ANCA; Glomerular and Tubulointerstitial Diseases; MPO ANCA; PR3 ANCA; RPGN; VASCULITIS; VENOUS THROMBOSIS

Mesh:

Substances:

Year:  2020        PMID: 35372925      PMCID: PMC8809268          DOI: 10.34067/KID.0000572019

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  18 in total

1.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

Review 2.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

3.  Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.

Authors:  Peter A Merkel; Grace H Lo; Janet T Holbrook; Andrea K Tibbs; Nancy B Allen; John C Davis; Gary S Hoffman; W Joseph McCune; E William St Clair; Ulrich Specks; Robert Spiera; Michelle Petri; John H Stone
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

4.  Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.

Authors:  Rami Abu-Fanne; Victoria Stepanova; Rustem I Litvinov; Suhair Abdeen; Khalil Bdeir; Mohamed Higazi; Emad Maraga; Chandrasekaran Nagaswami; Alexander R Mukhitov; John W Weisel; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2018-11-15       Impact factor: 22.113

5.  On the inhibitory effect of albumin on platelet aggregation.

Authors:  K A Jørgensen; E Stoffersen
Journal:  Thromb Res       Date:  1980 Jan 1-15       Impact factor: 3.944

6.  Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides.

Authors:  Andreas Kronbichler; Johannes Leierer; Gisela Leierer; Gert Mayer; Alina Casian; Peter Höglund; Kerstin Westman; David Jayne
Journal:  Rheumatology (Oxford)       Date:  2017-05-01       Impact factor: 7.580

7.  Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors.

Authors:  P M Stassen; R P H Derks; C G M Kallenberg; C A Stegeman
Journal:  Rheumatology (Oxford)       Date:  2008-04       Impact factor: 7.580

8.  High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients.

Authors:  Y Allenbach; R Seror; C Pagnoux; L Teixeira; P Guilpain; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

10.  Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis.

Authors:  Carmen E Mendoza; Elizabeth J Brant; Matthew L McDermott; Anne Froment; Yichun Hu; Susan L Hogan; J Charles Jennette; Ronald J Falk; Patrick H Nachman; Vimal K Derebail; Donna O'Dell Bunch
Journal:  Kidney Int Rep       Date:  2019-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.